Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia

(2015) Z. A. Hing et al.   BLOOD

XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A

(2015) T. Miyake et al.   CLINICAL CANCER RESEARCH

Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice

(2015) J Etchin et al.   LEUKEMIA

Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185

(2015) Yoko Tabe et al.   PLoS One

Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin

(2015) Michelandrea De Cesare et al.   Oncotarget

Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer

(2015) Jiankun Gao et al.   Oncotarget

A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis

(2014) S. Chen et al.   BLOOD

KPT-330 has antitumour activity against non-small cell lung cancer

(2014) H Sun et al.   BRITISH JOURNAL OF CANCER

KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma

(2014) Yun Zheng et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa)

(2014) Giovanni Gravina et al.   Journal of Hematology & Oncology

XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer

(2014) Y. Cheng et al.   MOLECULAR CANCER THERAPEUTICS

Cell-line authentication demystified

(2014) Vivien Marx   NATURE METHODS

Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma

(2014) Adam L. Green et al.   NEURO-ONCOLOGY

Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells

(2014) Xin-Yan Pei et al.   PLoS One

Specific Inhibition of the Nuclear Exporter Exportin-1 Attenuates Kidney Cancer Growth

(2014) Hiromi I. Wettersten et al.   PLoS One

Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents

(2014) Joel G. Turner et al.   SEMINARS IN CANCER BIOLOGY

Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma

(2013) Rachid C. Baz et al.   AMERICAN JOURNAL OF HEMATOLOGY

Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas

(2013) A. S. Azmi et al.   HAEMATOLOGICA

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

(2013) J Schmidt et al.   LEUKEMIA

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

(2013) Y-T Tai et al.   LEUKEMIA

CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma

(2013) R. A. Salas Fragomeni et al.   MOLECULAR CANCER THERAPEUTICS

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo

(2013) Joel G. Turner et al.   Journal of Cancer

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

(2012) R. Lapalombella et al.   BLOOD

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia

(2012) P. Ranganathan et al.   BLOOD

CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies

(2012) Shuang Chen et al.   CANCER RESEARCH

Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma

(2012) Kejie Zhang et al.   EXPERIMENTAL HEMATOLOGY

Selective Inhibitors of Nuclear Export Block Pancreatic Cancer Cell Proliferation and Reduce Tumor Growth in Mice

(2012) Asfar S. Azmi et al.   GASTROENTEROLOGY

Inhibition of CRM1-Mediated Nucleocytoplasmic Transport: Triggering Human Melanoma Cell Apoptosis by Perturbing Multiple Cellular Pathways

(2012) Gaurav Pathria et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

CRM1 Blockade by Selective Inhibitors of Nuclear Export Attenuates Kidney Cancer Growth

(2012) Hiromi Inoue et al.   JOURNAL OF UROLOGY

Nuclear export of proteins and drug resistance in cancer

(2011) Joel G. Turner et al.   BIOCHEMICAL PHARMACOLOGY

Human Multiple Myeloma Cells Are Sensitized to Topoisomerase II Inhibitors by CRM1 Inhibition

(2009) J. G. Turner et al.   CANCER RESEARCH

CRM1-Mediated Nuclear Export of Proteins and Drug Resistance in Cancer

(2008) Joel Turner et al.   CURRENT MEDICINAL CHEMISTRY